Assessing the impact of long-term omeprazole therapy: Across-sectional analysis of adverse effects"
DOI:
https://doi.org/10.54361/LJMR.19.1.02Keywords:
omeprazole, long term use, adverse effectAbstract
Background: Omeprazole is one of the most commonly prescribed of protein pump inhibitors (PPIs) drugs which used widely to manage many gastric acid-related conditions such as gastro esophageal disease, gastritis, esophagitis, Barrett’s esophagus, Zollinger-Ellison syndrome, peptic ulcer disease, nonsteroidal anti-inflammatory drug-associated ulcers, and Helicobacter pylori eradication, globally
.Aim of study: to evaluate the adverse effects associated with the long-term use of proton pump inhibitors drug( omeprazole).
Methodology : a descriptive study for 304 participants were conducted to fill a questionnaire to evaluate the adverse effect of long term use of omeprazole, data were analyzed statistically by SPSSV21.
Results: positive correlation between UTI infection and long term use of omeprazole . 66%of people who used omeprazole have deficiency in vitamin D, other side effects are showed in long term use of omeprazole as gastritis , confusion, .
Conclusion: because the improper use of omeprazole as a save drug more studies need to evaluate the risk of long term use of omeprazole.
Downloads
References
Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528-34.
Shin JM, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: structure, function, and inhibition. Pflügers Archiv-European J Physiol. 2009;457(3):609-22.
Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motility. 2018;24(2):182.
Galdo JA. Long-term consequences of chronic proton pump inhibitor use. US Pharm. 2013;38(12):38-42.
Sharma N, Chau WY, Dobruskin L. Effect of long-term proton pump inhibitor therapy on hemoglobin and serum iron levels after sleeve gastrectomy. Surgery for Obesity Related Diseases. 2019;15(10):1682-9.
Shikata T, Sasaki N, Ueda M, et al. Use of proton pump inhibitors is associated with anemia in cardiovascular outpatients. Circulation. 2014:CJ-14-0582.
Kaczmarczyk O, Przybylska-Feluś M, Piątek- Guziewicz A, et al. Effect of long-term proton pump inhibitor therapy on complete blood count parameters and selected trace elements: a pilot study. Polish Archives of Internal Medicine. 2020;130(3).
Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird- Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Digestive Diseases Sciences. 2011;56(8):2349-53.
Imai R, Higuchi T, Morimoto M, Koyamada R, Okada S. Iron deficiency anemia due to the long-term use of a proton pump inhibitor. Internal Medicine.
;57(6):899-901.
Krieg L, Milstein O, Krebs P, Xia Y, Beutler B, Du X. Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice. Blood. 2011;118(24):6418-25.
McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104:S5-S9.
Alkhalaylah AA, Hayajneh MM, Hijazeen SI, Alqhewii TA, Haddad ER, Alkhatib AJ. Study the overprescription of proton pump inhibitors and their relation with recurrent community aquired infections in outpatient refilled prescriptions of chronic diseases patients. Eur Sci J. 2016;12(6).
Ribeiro RHT, Ribeiro FA, Silva RPM, Bortolini MJS, Garrote-Filho MdS, Penha-Silva N. Depression, hematologic parameters, and blood levels of vitamin B12 in patients with laryngopharyngeal reflux under use of proton pump inhibitors. Clin Med Insights: Ear, Nose and Throat. 2019;12:1-7.
Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology . 2017;152:706–715 .
Gingold AR, Narasimhan G, Augello S, Clain DJ. The prevalence of proton pump inhibitor use in hospitalized patients. Am J Gastroenterol . 2004;99:S35–S36
Vatcharavongvan P, Puttawanchai V. Elderly patients in primary care are still at risks of receiving potentially inappropriate medications. J Prim Care Community Health 2021;12. doi: 10.1177/21501327211035088.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Nasrien Elfarrah, Abdulhakim Naffati, Hajer.Taher Ali, Amnna Salem Abudalal, Hanan Alhadi Thwer , Asmaa Absheenah (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
